Cannabis and Health

Module 12: Neurocognitive/Brain Disorders Part II

Lecture 4: Current Treatments for Parkinson's Disease and Alzheimer's Disease

- There is a contrast in the literature, where there are some drugs that improve cognitive functions (A)
- However, these drugs/improvements are less beneficial for global functioning (B; next slide)

RESEARCH Open Access

CrossMark

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network metaanalysis of 41 randomized controlled trials

Kai-Xin Dou¹, Meng-Shan Tan¹, Chen-Chen Tan¹, Xi-Peng Cao², Xiao-He Hou¹, Qi-Hao Guo³, Lan Tan^{1*}, Vincent Mok^{4.5,6} and Jin-Tai Yu^{1,7*}

Δ

Significantly in favor of active drug

Favors placebo

 Non-significant result 		SMD (95% Crl)
Donepezil 10 mg		0.15 (0.03 to 0.27)
Galantamine 24 mg		0.21 (0.08 to 0.34)
Rivastigmine 12 mg		0.21 (0.06 to 0.35)
Rivastigmine 5 cm ²	<u>:</u>	0.28 (-0.05 to 0.61)
Rivastigmine 10 cm ²		0.24 (0.07 to 0.41)
Rivastigmine 15 cm ²		0.42 (0.15 to 0.69)
Memantine 20 mg	-	0.12 (0.01 to 0.23)
Memantine 20 mg + Donepezeil 10 mg		0.32 (0.12 to 0.52)
-0.5	0	1.0

Favors active drug


- There is a contrast in the literature, where there are some drugs that improve cognitive functions (A)
- However, these drugs/improvements are less beneficial for global functioning (B)

RESEARCH Open Access



Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network metaanalysis of 41 randomized controlled trials

Kai-Xin Dou¹, Meng-Shan Tan¹, Chen-Chen Tan¹, Xi-Peng Cao², Xiao-He Hou¹, Qi-Hao Guo³, Lan Tan^{1*}, Vincent Mok^{4,5,6} and Jin-Tai Yu^{1,7*}



Side effects of AD medications

- Common side effects are usually mild and include:
 - diarrhea
 - vomiting
 - Nausea
 - fatigue
 - Insomnia
 - loss of appetite
 - weight loss



- The principal goals for dementia care are:
 - Early diagnosis, to promote early and optimal management
 - Optimizing physical health, cognition, activity, and well-being
 - Identifying and treating accompanying physical aspects of the illness
 - Detecting and treating challenging behavioural and psychological symptoms
 - Providing information and long-term support to caregivers



- Exercise programs may be beneficial for daily living and can potentially improve outcomes
 - A Cochrane Review provided a more nuanced picture
 - Exercise had moderate effects on dementia, overall (below)
 - But for moderate-severe cases, benefit was not significant (next slide)

	Exercise			Usual care				Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean SD		Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 Cognition: all tria	ls								
Christofoletti 2008	14.9	2.2	17	14.8	1.3	20	13.4%	0.06 [-0.59, 0.70]	
Eggermont 2009a	0.24	0.78	51	0.2	0.63	46	15.2%	0.06 [-0.34, 0.45]	
Eggermont 2009b	0.07	0.37	30	0.47	0.97	31	14.4%	-0.53 [-1.05, -0.02]	
Hwang 2010	28.9	11.86	10	24	14.68	8	11.0%	0.35 [-0.58, 1.29]	- •
Kemoun 2010	30.38	7.66	16	22.23	8.37	15	12.5%	0.99 [0.24, 1.74]	
Van de Winckel 2004	15.33	4.44	15	11	4.3	9	11.5%	0.95 [0.08, 1.83]	
Venturelli 2011	12	2	11	6	2	10	8.5%	2.88 [1.59, 4.17]	-
Vreugdenhil 2012	23.9	5	20	19	7.7	20	13.4%	0.74 [0.10, 1.38]	
Subtotal (95% CI)			170			159	100.0%	0.55 [0.02, 1.09]	~




- Exercise programs may be beneficial for daily living and can potentially improve outcomes
 - A Cochrane Review provided a more nuanced picture
 - Exercise had moderate effects on dementia, overall
 - But for moderate-severe cases, benefit was not significant (below)

1.1.2 Cognition: excluded moderate-severe dementia

Christofoletti 2008 Eggermont 2009a Eggermont 2009b Hwang 2010 Kemoun 2010 Van de Winckel 2004	14.9 0.24 0.07 28.9 30.38 15.33	2.2 0.78 0.37 11.86 7.66 4.44	17 51 30 10 16 15	14.8 0.2 0.47 24 22.23 11	1.3 0.63 0.97 14.68 8.37 4.3	20 46 31 8 15 9	14.7% 18.6% 16.8% 10.7% 13.1% 11.4%	0.06 [-0.59, 0.70] 0.06 [-0.34, 0.45] -0.53 [-1.05, -0.02] 0.35 [-0.58, 1.29] 0.99 [0.24, 1.74] 0.95 [0.08, 1.83]
			15 20	11 19		9 20	11.4% 14.7%	0.95 [0.08, 1.83]
Vreugdenhil 2012 Subtotal (95% CI)	23.9	5	1 59	19	7.7	149	100.0%	0.74 [0.10, 1.38] 0.31 [-0.11, 0.74]

Heterogeneity: $Tau^2 = 0.21$; $Chi^2 = 18.49$, df = 6 (P = 0.005); $I^2 = 68\%$

Test for overall effect: Z = 1.45 (P = 0.15)





Key therapeutic topics

Low-dose antipsychotics in people with dementia

Published: 31 January 2013

- Behavioural problems due to dementia have been treated with antipsychotics
- However, this is not recommended, as there is little benefit with an increased risk of early death
- There is some evidence that prescribing antipsychotics for dementia is on the decline
 - In the UK in 2011, there was a 10% decrease in the number of people with dementia receiving prescriptions for antipsychotics (from 17% in 2006 to 7% in 2011)
 - A 60% reduction in relative terms
 - Similarly, the proportion receiving an antipsychotic within a year of being diagnosed with dementia decreased by 10% (from 14% in 2006 to 4%), in 2011
 - A 69% reduction in relative terms



Treatments: Parkinson's


Meta-Analysis of the Comparative Efficacy and Safety of Adjuvant Treatment to Levodopa in Later Parkinson's Disease

Rebecca Stowe, PhD, ^{1*} Natalie Ives, MSc, ¹ Carl E. Clarke, MD, ^{2,3} Kelly Handley, PhD, ¹ Alexandra Furmston, PG Dip, ¹ Katherine Deane, PhD, ⁴ J.J. van Hilten, MD, ⁵ Keith Wheatley, D Phil, ⁶ Richard Gray, MSc ¹

- There is no cure for Parkinson's disease, but treatments can improve symptoms
 - Initial treatment is typically with the anti-Parkinson medication levodopa (L-DOPA; a dopamine precursor)

Dopamine agonists are used once levodopa becomes less

effective



Review

Treatments: Parkinson's

Major Nutritional Issues in the Management of Parkinson's Disease

Michela Barichella, MD,¹ Emanuele Cereda, MD,^{1,2*} and Gianni Pezzoli, MD¹

- As the disease progresses and neurons are lost, dopaminergic medications become less effective
 - Regular exercise is helpful
 - Nutritional interventions could also be planned to to prevent weight changes and may help diminish nutritional deficiencies
 - Diet and some forms of rehabilitation have shown some effectiveness at improving symptoms (see right for a model)




FIG. 3. A potential nutritional treatment pyramid for patients with PD in relation to stage of disease.

Treatments: Parkinson's

- Anti-Parkinson's medications (levodopa carbidopa) have limitations
 - Evidence for treating non-movement symptoms of PD (e.g., sleep disturbances, emotional problems) is weak
 - Dopaminergic medications also produce long-term complications (e.g., involuntary movements)

 Anxiety, irritability, depression, sleep disturbance, pain are examples of symptoms that are not treated with PD specific medications

Conclusions

- Exercise intervention is important EARLY in the course of AD
- Exercise intervention is also important in PD
- There are medications that may modestly helpful for the cognitive effects of AD, less so for global functioning
 - Antipsychotics used for behavioral symptoms bad side effects
- Several medications are helpful for PD motor symptoms, less so for non-motor symptoms